The 24th International AIDS Conference (AIDS 2022), 29 July-2 August 2022, Montreal, Canada and virtually

项目摘要 在过去的40年里，艾滋病毒科学的进步是显着的，人们的预期寿命接近正常。 为正在接受抗病毒治疗的人提供更多的机会，并不断扩大获得预防、治疗和护理的机会。但我们 没有有效的艾滋病毒疫苗或治愈全球3700万艾滋病毒感染者的方法。的 2021年6月联合国关于艾滋病毒和艾滋病问题的政治宣言设定了新的目标，并对以下问题作出了令人欢迎的澄清： 实现这些目标所需的政策干预和资源投资的广度。但这些将 只有当证据为政策提供信息，科学创新继续提供更好的服务时， 解决剩余的生物医学，社会行为和实施挑战。一次全球会议， 因此，科学家、临床医生、受影响的社区领导、实施者、捐助者和政治领导人共同努力， 迫切需要批判性地确定未来的研究议程，将新的证据转化为行动，并制定新的 在实现仍然难以实现的艾滋病毒大流行病控制目标方面，我们达成了共识。艾滋病2022的主题是“重新参与”， “科学”就是这种紧迫感的缩影。 认识到COVID-19疫苗的不均衡推出可能会阻止许多关键利益相关者，特别是 在国际旅行造成艾滋病毒高负担的国家，艾滋病2022将是一次完全混合的会议 (29 2022年7月至8月2日）。除了虚拟会议平台外，蒙特利尔还将提供一个引人注目的场地 2022年艾滋病作为艾滋病毒科学的领先中心，着眼于进步的加拿大政策环境 并承认加拿大在全球合作应对这一流行病方面发挥的领导作用。 艾滋病2022的具体目标是： 1.加快科学发现，推动艾滋病毒预防和治疗级联的创新， 包括发病机制、传播、疫苗、缓解和功能性治愈;长效口服和 注射治疗和预防技术，包括预防环;综合和有区别的 保健模式;以及健康的结构和经济决定因素分析。 2.加快更新治疗指南，特别是针对低收入和中等收入国家， 儿童和艾滋病毒、结核病、病毒性肝炎和COVID-19感染者。 3.促进适应来自应对COVID-19的跨科学、政策和 实践和巩固防范大流行病的良好做法，以及免疫工作，包括新的 公共和私营利益攸关方之间的伙伴关系以及从艾滋病毒应对措施的调整中吸取的经验教训 加快了对COVID-19的反应。 4.推进实施科学研究的核心组成部分，以应对挑战， 在一系列流行病背景下和COVID-19时代的整合机会，包括研究结果 社区主导的研究、监测和服务提供创新，包括远程医疗。 5.解决关键群体和边缘群体艾滋病毒感染脆弱性和疾病进展的决定因素 人口，包括新的干预措施和实施科学，以减少耻辱和歧视， 包括对艾滋病毒的交叉污名，同性恋恐惧症，跨性别恐惧症，以及种族和种族差异， 土著/第一民族社区中的行为以及将这些行为定为刑事犯罪的影响， 性关系、非法药物使用和性工作。 6.提请注意艾滋病毒应对工作中的长期差距，例如需要加大投资的领域 在研究和以人为本的服务提供方面，社区的需求仍然被忽视。 科学计划将包括六个轨道：轨道A/基础和转化研究;轨道B/临床 研究;轨道C/流行病学和预防科学;轨道D/社会和行为研究;轨道E/ 实施研究，经济学，系统和协同与其他卫生和发展部门;和 政治研究、法律、政策和人权。虽然会议的科学计划是 由代表不同学科和科学领域的国际跟踪委员会开发， 切割方面将在全体会议上讨论，也连接科学轨道与社区， 领导视角。此外，桥接会议旨在跨越至少两个科学领域， 轨道，为多学科、多视角的对话提供机会，通常采用互动形式。 青年研究人员、基础科学家和相关领域的研究人员的参与， 通过积极开展相关科学研究， 具体的财政支持，以及远程访问选项。会议的关键科学将是 在艾滋病2022年之后在区域范围内传播和讨论。

Project Summary The advances in HIV science across the past 40 years have been remarkable, with near normal life expectancy for persons on antiviral therapy and ever widening access to prevention, treatment and care. However, we do not have an effective HIV vaccine or a cure for the 37 million people living with HIV infection worldwide. The June 2021 United Nations Political Declaration on HIV and AIDS sets new targets and offers welcome clarity on the breadth of policy interventions and resource investments required to meet these objectives. But these will only become a reality if evidence informs policy and scientific innovation continues to provide ever better solutions to remaining biomedical, socio-behavioral and implementation challenges. A global convening bringing together scientists, clinicians, affected community leadership, implementers, donors, and political leaders is thus urgently needed to critically define future research agendas, shift new evidence to action and chart a new consensus on achieving the still elusive goal of pandemic control of HIV. The theme of AIDS 2022, “Re-engage & follow the science” epitomizes this urgency. Recognizing that uneven rollout of COVID-19 vaccines will likely prevent many key stakeholders particularly from countries with a high burden of HIV from travelling internationally, AIDS 2022 will be a fully hybrid conference (29 July-2 August 2022). In addition to the virtual conference platform, Montreal will provide a compelling venue for AIDS 2022 as a leading center of HIV science, with a view to the progressive Canadian policy environment for those at risk and in recognition of Canadian leadership in global cooperation to address the epidemic. Specific aims for AIDS 2022 are to: 1. Accelerate scientific discovery to drive innovation across the HIV prevention and treatment cascades, including pathogenesis, transmission, vaccines, remission and a functional cure; long-acting oral and injectable treatment and prevention technologies, including rings for prevention; integrated and differentiated models of care; and analyses of structural and economic determinants of health. 2. Accelerate updates to treatment guidance especially for low and middle-income countries, infected children and persons with HIV, TB, viral hepatitis and COVID-19 infection. 3. Facilitate the adaptation of innovations from the response to COVID-19 across science, policy and practice and consolidating good practice for pandemic preparedness, and immunization efforts including new partnerships between public and private stakeholders and learnings from adaptations from the HIV response that accelerated the response to COVID-19. 4. Advance core components of implementation science research that address the challenges and opportunities of integration across a range of epidemic settings and in the COVID-19 era, including findings from community-led research, monitoring and innovations in service delivery, including telemedicine. 5. Address HIV vulnerability and determinants of disease progression among key and marginalized populations, including novel interventions and implementation science to reduce stigma and discrimination, including intersectional stigmas of HIV, homophobia, transphobia, and ethnic and racial disparities, including those among indigenous/first nation communities and impact of criminalization of behaviours including same- sex relationships, illicit drug use, and sex work. 6. Draw attention to enduring gaps in the HIV response, such as areas where greater investment is needed in research and person-centered service delivery, and where the needs of communities remain neglected. The scientific program will consist of six tracks: Track A/Basic and Translational Research; Track B/Clinical Research; Track C/Epidemiology and Prevention Science; Track D/Social and Behavioral Research; Track E/ Implementation Research, Economics, Systems and Synergies with other Health and Development Sectors; and Track F/Political research, law, policy and human rights. While the scientific program of the conference is developed by international track committees that represent different disciplines and areas of science, cross- cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives. Additionally, bridging sessions are designed to cut across at least two of the scientific tracks to provide opportunities for multi-disciplinary, multi-perspective dialogues, often using interactive formats. The participation of young researchers, basic scientists and researchers in related fields such as non- communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support, in addition to remote-access options. Key science from the conference will be disseminated and discussed in regional contexts following AIDS 2022.